Metformin-mediated growth inhibition involves suppression of the IGF-I receptor signalling pathway in human pancreatic cancer cells

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Karnevi, Emelie ^a   Said, Katarzyna ^a   Andersson, Roland ^a   Rosendahl, Ann H ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Hyperglycaemia; Insulin like growth factor (IGF); Metformin; Pancreatic cancer; Signalling; Type 2 diabetes mellitus

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; METFORMIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE B; SOMATOMEDIN C;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; HYPERGLYCEMIA; IN VITRO STUDY; PANCREAS ADENOCARCINOMA; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION; UPREGULATION;

AMP-ACTIVATED PROTEIN KINASES; ANALYSIS OF VARIANCE; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RECEPTOR SUBSTRATE PROTEINS; METFORMIN; PANCREATIC NEOPLASMS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION;

EID: 84877251996     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-235     Document Type: Article

References (38)

1. Pisani P. Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies. Arch Physiol Biochem 2008, 114(1):63-70. 10.1080/13813450801954451, 18465360.
2. Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 2005, 92(11):2076-2083. 10.1038/sj.bjc.6602619, 2361795, 15886696.
3. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults. N Engl J Med 2003, 348(17):1625-1638. 10.1056/NEJMoa021423, 12711737.
4. Becker S, Dossus L, Kaaks R. Obesity related hyperinsulinaemia and hyperglycaemia and cancer development. Arch Physiol Biochem 2009, 115(2):86-96. 10.1080/13813450902878054, 19485704.
5. Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA 1995, 273(20):1605-1609. 10.1001/jama.1995.03520440059037, 7745774.
6. Bao B, Wang Z, Li Y, Kong D, Ali S, Banerjee S, Ahmad A, Sarkar FH. The complexities of obesity and diabetes with the development and progression of pancreatic cancer. Biochim Biophys Acta 2011, 1815(2):135-146. 3056906, 21129444.
7. Michaud DS, Wolpin B, Giovannucci E, Liu S, Cochrane B, Manson JE, Pollak MN, Ma J, Fuchs CS. Prediagnostic plasma C-peptide and pancreatic cancer risk in men and women. Cancer Epidemiol Biomarkers Prev 2007, 16(10):2101-2109. 10.1158/1055-9965.EPI-07-0182, 17905943.
8. Larsson SC, Orsini N, Wolk A. Body mass index and pancreatic cancer risk: a meta-analysis of prospective studies. Int J Cancer 2007, 120(9):1993-1998. 10.1002/ijc.22535, 17266034.
9. Pannala R, Basu A, Petersen GM, Chari ST. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol 2009, 10(1):88-95. 10.1016/S1470-2045(08)70337-1, 2795483, 19111249.
10. Bartosch-Harlid A, Andersson R. Diabetes mellitus in pancreatic cancer and the need for diagnosis of asymptomatic disease. Pancreatology 2010, 10(4):423-428. 10.1159/000264676, 20720443.
11. Stattin P, Bjor O, Ferrari P, Lukanova A, Lenner P, Lindahl B, Hallmans G, Kaaks R. Prospective study of hyperglycemia and cancer risk. Diabetes Care 2007, 30(3):561-567. 10.2337/dc06-0922, 17327321.
12. Grote VA, Rohrmann S, Nieters A, Dossus L, Tjonneland A, Halkjaer J, Overvad K, Fagherazzi G, Boutron-Ruault MC, Morois S. Diabetes mellitus, glycated haemoglobin and C-peptide levels in relation to pancreatic cancer risk: a study within the european prospective investigation into cancer and nutrition (EPIC) cohort. Diabetologia 2011, 54(12):3037-3046. 10.1007/s00125-011-2316-0, 21953276.
13. Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, Whincup PH, Mukamal KJ, Gillum RF, Holme I. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011, 364(9):829-841.
14. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008, 8(12):915-928. 10.1038/nrc2536, 19029956.
15. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, Montminy M, Cantley LC. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005, 310(5754):1642-1646. 10.1126/science.1120781, 3074427, 16308421.
16. United Kingdom Prospective Diabetes Study (UKPDS) 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995, 310(6972):83-88. 2548496, 7833731, United Kingdom Prospective Diabetes Study (UKPDS).
17. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352(9131):854-865.
18. Li D, Abbruzzese JL. New strategies in pancreatic cancer: emerging epidemiologic and therapeutic concepts. Clin Cancer Res 2010, 16(17):4313-4318. 10.1158/1078-0432.CCR-09-1942, 2932833, 20647474.
19. Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009, 137(2):482-488. 10.1053/j.gastro.2009.04.013, 2735093, 19375425.
20. Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, Gandini S. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila) 2010, 3(11):1451-1461.
21. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009, 52(9):1766-1777. 10.1007/s00125-009-1440-6, 19572116.
22. Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer 2009, 9(8):563-575. 10.1038/nrc2676, 2756045, 19629071.
23. Schneider MB, Matsuzaki H, Haorah J, Ulrich A, Standop J, Ding XZ, Adrian TE, Pour PM. Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology 2001, 120(5):1263-1270. 10.1053/gast.2001.23258, 11266389.
24. Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti JF, Le Marchand-Brustel Y, Bost F. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008, 27(25):3576-3586. 10.1038/sj.onc.1211024, 18212742.
25. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006, 66(21):10269-10273. 10.1158/0008-5472.CAN-06-1500, 17062558.
26. Rosendahl AH, Gundewar C, Said K, Karnevi E, Andersson R. Celecoxib synergizes human pancreatic ductal adenocarcinoma cells to sorafenib-induced growth inhibition. Pancreatology 2012, 12(3):219-226.
27. Qanungo S, Haldar S, Basu A. Restoration of silenced peutz-jeghers syndrome gene, LKB1, induces apoptosis in pancreatic carcinoma cells. Neoplasia 2003, 5(4):367-374. 1502423, 14511408.
28. Zhuang Y, Miskimins WK. Metformin induces both caspase-dependent and poly(ADP-ribose) polymerase-dependent cell death in breast cancer cells. Mol Cancer Res 2011, 9(5):603-615. 10.1158/1541-7786.MCR-10-0343, 3096726, 21422199.
29. Zakikhani M, Blouin MJ, Piura E, Pollak MN. Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells. Breast Cancer Res Treat 2010, 123(1):271-279. 10.1007/s10549-010-0763-9, 20135346.
30. Algire C, Amrein L, Bazile M, David S, Zakikhani M, Pollak M. Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo. Oncogene 2011, 30(10):1174-1182. 10.1038/onc.2010.483, 21102522.
31. Ning J, Xi G, Clemmons DR. Suppression of AMPK activation via S485 phosphorylation by IGF-I during hyperglycemia is mediated by AKT activation in vascular smooth muscle cells. Endocrinology 2011, 152(8):3143-3154. 10.1210/en.2011-0155, 3138225, 21673100.
32. Gonzalez-Angulo AM, Meric-Bernstam F. Metformin: a therapeutic opportunity in breast cancer. Clin Cancer Res 2010, 16(6):1695-1700. 10.1158/1078-0432.CCR-09-1805, 2840206, 20215559.
33. Sinnett-Smith J, Kisfalvi K, Kui R, Rozengurt E. Metformin inhibition of mTORC1 activation, DNA synthesis and proliferation in pancreatic cancer cells: dependence on glucose concentration and role of AMPK. Biochem Biophys Res Commun 2013, 430(1):352-357. 10.1016/j.bbrc.2012.11.010, 23159620.
34. Garcia-Haro L, Garcia-Gimeno MA, Neumann D, Beullens M, Bollen M, Sanz P. Glucose-dependent regulation of AMP-activated protein kinase in MIN6 beta cells is not affected by the protein kinase a pathway. FEBS Lett 2012, 586(23):4241-4247. 10.1016/j.febslet.2012.10.032, 23116618.
35. Hahn-Windgassen A, Nogueira V, Chen CC, Skeen JE, Sonenberg N, Hay N. Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. J Biol Chem 2005, 280(37):32081-32089. 10.1074/jbc.M502876200, 16027121.
36. Magruder JT, Elahi D, Andersen DK. Diabetes and pancreatic cancer: chicken or egg?. Pancreas 2011, 40(3):339-351. 10.1097/MPA.0b013e318209e05d, 21412116.
37. Ning J, Clemmons DR. AMP-activated protein kinase inhibits IGF-I signaling and protein synthesis in vascular smooth muscle cells via stimulation of insulin receptor substrate 1 S794 and tuberous sclerosis 2 S1345 phosphorylation. Mol Endocrinol 2010, 24(6):1218-1229. 10.1210/me.2009-0474, 2875806, 20363874.
38. Memmott RM, Mercado JR, Maier CR, Kawabata S, Fox SD, Dennis PA. Metformin prevents tobacco carcinogen-induced lung tumorigenesis. Cancer Prev Res (Phila) 2010, 3(9):1066-1076.